Q3 25 EPS
$1.86
BEAT +359.83%
Est. $0.40
Q3 25 Revenue
$288.8M
BEAT +1.80%
Est. $283.7M
vs S&P Since Q3 25
-8.5%
TRAILING MARKET
FRPT -1.0% vs S&P +7.5%
Market Reaction
Did FRPT Beat Earnings? Q3 2025 Results
Freshpet delivered a headline-grabbing Q3 2025 beat, with GAAP earnings per share of $1.86 eclipsing the $0.40 consensus estimate by 359.83%, though the result was heavily shaped by a one-time $77.90 million deferred tax asset valuation allowance rel… Read more Freshpet delivered a headline-grabbing Q3 2025 beat, with GAAP earnings per share of $1.86 eclipsing the $0.40 consensus estimate by 359.83%, though the result was heavily shaped by a one-time $77.90 million deferred tax asset valuation allowance release that drove net income to $101.66 million. Strip away that discrete tax benefit and the underlying story remains constructive: net sales grew 14.0% year-over-year to $288.85 million, edging past the $283.73 million consensus by 1.80%, propelled by volume gains of 12.9% and favorable price/mix of 1.1%. Adjusted EBITDA climbed to $54.61 million, with margin expanding 170 basis points to 18.9%. Looking ahead, management trimmed full-year 2025 guidance to reflect a more cautious consumer backdrop, narrowing net sales growth to approximately 13% and Adjusted EBITDA to $190 to $195 million, while reducing capital expenditures to roughly $140 million; the company now expects to be free cash flow positive for the full year, a milestone reached one year ahead of its original target.
Key Takeaways
- • Volume gains of 12.9% drove majority of 14.0% net sales growth
- • Favorable price/mix of 1.1%
- • Household penetration growth of 10% YoY to approximately 14.8 million households
- • MVP household penetration growth of 15% YoY
- • Input costs as a percentage of net sales decreased 50 basis points YoY
- • SG&A as percentage of net sales decreased 480 basis points due to lower share-based compensation and variable compensation accruals
- • Discrete $77.9 million deferred tax benefit from release of valuation allowance due to sustained profitability
FRPT YoY Financials
Q3 2025 vs Q3 2024, source: SEC Filings
“We are quickly adjusting to the new economic reality and remain one of the best performing pet food businesses—with strong financial and operational results and category-leading growth.”
— Billy Cyr, Q3 2025 Earnings Press Release
FRPT Earnings Trends
FRPT vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
FRPT EPS Trend
Earnings per share: estimate vs actual
FRPT Revenue Trend
Quarterly revenue: estimate vs actual
FRPT Quarterly Results
5 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q1 26 BEAT | $0.09 | $0.91 | +929.41% | $297.6M | +2.10% |
| Q4 25 BEAT FY | $0.48 | $0.64 | +34.31% | $285.2M | -0.17% |
| FY Full Year | $2.73 | $2.64 | -3.39% | $1.10B | -0.05% |
| Q3 25 BEAT | $0.40 | $1.86 | +359.83% | $288.8M | +1.80% |
| Q2 25 BEAT | $0.16 | $0.33 | +112.90% | $264.7M | -1.21% |
| Q1 25 MISS | $0.09 | $-0.26 | -385.40% | $263.2M | +1.93% |